Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice
Y. Jang, H. Cho, J. Chun, K. Park, A. Nowakowska, J. Kim, H. Lee, C. Lee, Y. Han, H.-J. Lee, H.-Y. Shin, Y. B. Kim
This paper develops a baculoviral DNA vaccine targeting the SARS-CoV2 Delta variant, showing 100% survival against Delta and Omicron in mice, compared to 50% survival with the original vaccine.
bioRxiv · Oct 7, 2022Immunology